Results 1 to 10 of about 88,356 (287)
Antibody drug conjugates [PDF]
Indian Journal of Medical and Paediatric Oncology, 2020 Antibody drug conjugates (ADCs) are chemically engineered drugs consisting of monoclonal antibody (mAb) and cytotoxic compound attached chemically by a linker. Upon attachment to a specific target antigen, ADC enters into the cell and payload is released,
Stalin Bala, Siva K Prasad
doaj +7 more sources
Exploration of the antibody–drug conjugate clinical landscape
mAbs, 2023 The antibody–drug conjugate (ADC) field has undergone a renaissance, with substantial recent developmental investment and subsequent drug approvals over the past 6 years. In November 2022, ElahereTM became the latest ADC to be approved by the US Food and
Heather Maecker +4 more
doaj +3 more sources
Applications of Pharmacometrics in Antibody–Drug Conjugate Development [PDF]
PharmaceuticsAntibody–drug conjugates (ADCs), which integrate a cytotoxic drug known as the payload into a tumor-targeting monoclonal antibody via a linker, have emerged as promising candidates for cancer therapy and are a new avenue for targeted cancer therapy.
Xiaoliang Cheng +3 more
doaj +2 more sources
CD74-Targeted Cathepsin-Inhibitor Antibody–Drug Conjugate Triggers Apoptosis in DLBCL [PDF]
CellsTranscriptomic analyses of public datasets (TCGA and GTEx) revealed that both CD74 and Cathepsin L (CTSL) are significantly overexpressed in diffuse large B-cell lymphoma (DLBCL) compared to normal tissues, and that their expression levels are highly ...
Ihab Abd-Elrahman +7 more
doaj +2 more sources
Novel Immune Checkpoint Inhibitor and Antibody–Drug Conjugate Approaches in the Perioperative Management of Muscle-Invasive Bladder Cancer [PDF]
Current OncologyImmune checkpoint inhibitors and antibody drug conjugate combinations have revolutionized the management of patients with advanced and metastatic urothelial carcinoma, offering unprecedented survival outcomes. These treatments are now moving into earlier
Joseph Vento +4 more
doaj +2 more sources
HER2‐Targeted Antibody‐Drug Conjugate Toxicities in Breast Cancer [PDF]
Cancer MedicineBackground HER2‐targeted antibody‐drug conjugates (ADCs) have dramatically advanced breast cancer outcomes. Two HER2‐targeted ADCs, trastuzumab deruxtecan and trastuzumab emtansine, are currently approved for use in breast cancer, with > 60 other ...
Seohyuk Lee +5 more
doaj +2 more sources
Antibody–drug conjugates [PDF]
Proceedings of the National Academy of Sciences, 2013 Ideally, targeted therapies attack diseased cells while leaving healthy ones alone. It’s a strategy that could result in more effective treatments for cancer (or other diseases) with fewer toxic side effects than traditional chemotherapies. A burgeoning class of targeted therapies, called antibody–drug conjugates (ADC), deliver dual therapies in a ...
Beck, Alain, Reichert, Janice M.
+8 more sources
Antibody-Drug Conjugates [PDF]
Pharmaceutical Research, 2015 Antibody-drug conjugates (ADCs) are an exciting and new class of therapeutic modalities that have gained significant traction over the past few years – specifically in the field of oncology. With the recent approvals of CD-30 directed Adcetris® (brentuximab vedotin) and the Her2 targeted Kadcyla® (ado-trastuzumab emtansine) and hundreds of other ADCs ...
Ashutosh A, Kulkarni +1 more
+7 more sources
Pharmaceuticals, 2022 Although there have been extensive research and progress on the discovery of anticancer drug over the years, the application of these drugs as stand-alone therapy has been limited by their off-target toxicities, poor pharmacokinetic properties, and low ...
Audrey Nathania Johan, Yi Li
doaj +1 more source
Antibody–Drug Conjugate to Treat Meningiomas
Pharmaceuticals, 2021 Meningiomas are primary tumors of the central nervous system with high recurrence. It has been reported that somatostatin receptor 2 (SSTR2) is highly expressed in most meningiomas, but there is no effective targeted therapy approved to control ...
Kai Chen +9 more
doaj +1 more source